CytomX Therapeutics, Inc. (CTMX) Earnings History
Annual and quarterly earnings data from 2013 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 100.0% | 18.1% | 23.1% |
| 2023 | 100.0% | -6.4% | -0.6% |
| 2022 | 100.0% | -190.6% | -186.8% |
| 2021 | 100.0% | -311.0% | -310.5% |
| 2020 | 100.0% | -117.7% | -94.7% |
Download Data
Export CTMX earnings history in CSV or JSON format
Free sign-in required to download data
CytomX Therapeutics, Inc. (CTMX) Earnings Overview
As of February 28, 2026, CytomX Therapeutics, Inc. (CTMX) reported trailing twelve-month net income of $28M. The company earned $0.17 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, CTMX's historical earnings data spans multiple years. The company achieved its highest annual net income of $32M in fiscal 2024, representing a new all-time high.
CytomX Therapeutics, Inc. maintains positive profitability with a gross margin of 1.0%, operating margin of 0.2%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including REGN ($4.50B net income, 0.3% margin), CNTA (-$243M net income), IMNM (-$223M net income, -32.4% margin), CTMX has room to improve margins relative to the peer group. Compare CTMX vs REGN →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
12 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $32M | +5700.9% | $25M | $0.38 | 23.1% | 18.1% |
| 2023 | $-569,000 | +99.4% | -$6M | $-0.01 | -0.6% | -6.4% |
| 2022 | -$99M | +14.3% | -$101M | $-1.48 | -186.8% | -190.6% |
| 2021 | -$116M | -78.8% | -$116M | $-1.26 | -310.5% | -311.0% |
| 2020 | -$65M | +36.6% | -$81M | $-0.71 | -94.7% | -117.7% |
| 2019 | -$102M | -20.8% | -$111M | $-2.26 | -177.8% | -192.9% |
| 2018 | -$85M | -96.3% | -$78M | $-2.03 | -142.2% | -130.9% |
| 2017 | -$43M | +26.8% | -$46M | $-1.16 | -60.2% | -64.6% |
| 2016 | -$59M | -66.5% | -$60M | $-1.63 | -391.5% | -396.1% |
| 2015 | -$35M | -16.7% | -$33M | $-1.00 | -458.7% | -430.5% |
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CTMX vs AGIO
See how CTMX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CTMX growing earnings?
CTMX TTM EPS: $0.17. Net income: $28M. Earnings growth: N/A.
What are CTMX's profit margins?
CytomX Therapeutics, Inc. net margin is +0.2%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are CTMX's earnings?
CTMX earnings data spans 2013-2024. The current earnings trend is N/A YoY. Historical data enables comparison across business cycles.